NORMAN J CLEMENT RPH., DDS, NORMAN L. CLEMENT PHARM-TECH, MALACHI F. MACKANDAL PHARMD, BELINDA BROWN-PARKER, IN THE SPIRIT OF JOSEPH SOLVO ESQ., INC., SPIRIT OF REV. IN THE SPIRIT OF WALTER R. CLEMENT BS., MS, MBA. HARVEY JENKINS, MD, PH.D., IN THE SPIRIT OF C.T. VIVIAN, JELANI ZIMBABWE CLEMENT, BS., M.B.A., IN THE SPIRIT OF THE HON. PATRICE LUMUMBA, IN THE SPIRIT OF ERLIN CLEMENT SR., EVELYN J. CLEMENT, WALTER F. WRENN III., MD., JULIE KILLINGSWORTH, RENEE BLARE, RPH, DR. TERENCE SASAKI, MD LESLY POMPY MD., CHRISTOPHER RUSSO, MD., NANCY SEEFELDT, IN THE SPIRIT OF WILLIE GUINYARD BS., JOSEPH WEBSTER MD., MBA, BEVERLY C. PRINCE MD., FACS., NEIL ARNAND, MD., IN THE SPIRIT OF RICHARD KAUL, MD., IN THE SPIRIT OF LEROY BAYLOR, JAY K. JOSHI MD., MBA, AISHA GARDNER, ADRIENNE EDMUNDSON, ESTER HYATT PH.D., WALTER L. SMITH BS., IN THE SPIRIT OF BRAHM FISHER ESQ., MICHELE ALEXANDER MD., CUDJOE WILDING BS, MARTIN NJOKU, BS., RPH., IN THE SPIRIT OF DEBRA LYNN SHEPHERD, BERES E. MUSCHETT, STRATEGIC ADVISORS
Originally Published on Facebook
EXPOSING THE DEA’S DECEPTION AND DIVERSION OF THE TRUTH IN THE CASE OF PRONTO PHARMACY, TAMPA, Fl
The recent Fifth Circuit decision in Neumann’s FEB 16 2026! Pharmacy v. Drug Enforcement Administration is an important development in federal controlled substance law.
While it does not directly control cases outside the Fifth Circuit, its reasoning places meaningful limits on the DEA’s interpretation of pharmacists’ responsibility under the Controlled Substances Act.
Because of that, the decision has potential value for arguments raised by individuals such as Dr. Clement.
First, the court clarified the scope of a pharmacist’s legal duty. Federal regulation requires that controlled substance prescriptions be issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice.
The regulation also states that pharmacists share a corresponding responsibility to ensure the prescription is legitimate. The DEA has often interpreted this language very broadly and has treated pharmacists as responsible for identifying and refusing prescriptions whenever the agency later claims “red flags” were present. The Fifth Circuit rejected that expansive interpretation.
NEUMANN CREATED THE GAME CHANGER IN THE PRACTICE OF PHARMACY
The court emphasized that a pharmacist cannot be held liable simply because the government later identifies suspicious characteristics in a prescription. The key issue is knowledge.
A pharmacist must know that the prescription is not legitimate before liability can attach. Suspicion, hindsight evaluation, or disagreement with a physician’s judgment is not enough.
This clarification is significant because DEA enforcement actions frequently rely on patterns or circumstances rather than direct proof that a pharmacist knew the prescription lacked a legitimate medical purpose.
Examples commonly cited by investigators include dosage levels, travel distance between patient and pharmacy, combinations of medications, or prescribing volume.
The Fifth Circuit’s reasoning indicates that these kinds of factors may create suspicion, but they do not by themselves establish the required knowledge of illegitimacy.
Second, the court addressed the phrase “usual course of professional practice.” The DEA has often used this language as a broad enforcement tool, effectively turning it into a negligence standard.
Under that approach, if a pharmacist failed to investigate or question a prescription as aggressively as the DEA believes they should have, the agency could claim a violation of federal law.
The Fifth Circuit rejected that approach. The court explained that federal law does not convert ordinary professional judgment into a federal enforcement standard. The Controlled Substances Act does not authorize the DEA to transform disagreements about pharmacy practice into federal violations unless the statutory elements are satisfied. In other words, federal law cannot simply federalize state malpractice or professional discipline standards.
Third, the decision indirectly weakens the long-standing “red flag” enforcement model used by the DEA. Over many years, the agency has built enforcement cases around the concept that pharmacists must identify and resolve “red flags.” However, the statute and its implementing regulations do not define that term. The Fifth Circuit’s reasoning suggests that enforcement based primarily on undefined warning signs without proof of actual knowledge is legally vulnerable.
When looking at the arguments raised by Dr. Clement in his Supreme Court filing, the Neumann decision touches several themes that appear in his petition. His filing repeatedly argues that pharmacies were punished for filling prescriptions written by licensed physicians even though investigators failed to show the prescriptions were illegitimate.
The petition also argues that enforcement relied heavily on vague red flag concepts rather than statutory standards. The Fifth Circuit’s reasoning gives some support to those concerns by reinforcing the requirement that liability must be tied to clear statutory elements, not generalized suspicion.
There is, however, an important limitation to understand. The Neumann decision does not automatically overturn or reopen prior enforcement actions. It also does not bind courts outside the Fifth Circuit. A case arising in another circuit would treat the decision as persuasive authority rather than controlling law. Courts may consider its reasoning, but they are not required to follow it.
Even with that limitation, the decision represents a shift in how at least one federal appellate court is viewing DEA enforcement theories. For many years courts tended to defer heavily to the agency’s interpretation of pharmacist responsibility. The Fifth Circuit’s ruling signals that courts are increasingly willing to scrutinize those interpretations more carefully and insist on adherence to the statutory text.
In practical terms, the Neumann decision supports arguments challenging enforcement based primarily on generalized suspicion, statistical patterns, or undefined regulatory expectations. It reinforces the idea that federal liability must be tied to clear proof that a pharmacist knew a prescription lacked a legitimate medical purpose.
For someone in Dr. Clement’s position, the decision does not guarantee relief, but it strengthens the broader legal argument that federal enforcement cannot rely on vague standards or hindsight analysis of medical practice. It underscores the principle that the Controlled Substances Act regulates unlawful distribution of drugs, not ordinary professional judgment in medicine and pharmacy.
🔓 🔓 🔓
ALL WATCHED OVER BY MACHINES OF LOVING GRACE
BE SURE TO DONATE TO THE MARK IBSEN GOFUNDME DEFENSE FUND, WHERE THE SON ALWAYS RISES!!!
OUR TREE OF KNOWLEDGE SHALL NEVER BE SUPPRESSED
FOR NOW, YOU ARE WITHIN
THE NORMS
REFERENCES:
The Pharmacist’s Dilemma December 19, 2025
I am so confused.
So the pharmacist is supposed to resolve a red flag that the prescription is “legitimate?”
“Legitimate” according to whom?
The medical board? The DEA?
And what if the prescription is in excess of some arbitrary and capricious dose cap that has been placed by either of these regulatory groups? And what if the doctor remains of the opinion that the prescription is necessary? The pharmacist can disagree? That sounds like way too much authority being given to a pharmacist. I want to scream!
That’s what we have been articulating these MANY years and the governing professional boards failed IN their mandate specifically TO the public! Now thousands of people suffering chronic diseases have perished as the result of DEA OVERREACH INTO MEDICINE